Summary

Overview
Global Self-injection Device market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Autoinjectors are a very useful class of medical devices that enable self-injection of drugs via the subcutaneous or intramuscular routes. They are equipped with prefilled syringes or cartridges and a spring mechanism that aids in the injection process. These devices have numerous advantages like easy self-administration, better patient compliance, reduced anxiety, and precise dosage delivery. Autoinjectors are used for both emergency and chronic conditions such as anaphylaxis, migraine, status epilepticus, psoriasis, diabetes, multiple sclerosis, and rheumatoid arthritis.
Market Dynamics: Drivers & Restraints
Increasing Product Launches
The increasing product launches in the market are expected to boost the global market growth during the forecast period. For instance, in September 2022, Owen Mumford Pharmaceutical Services launched its latest Aidaptus auto-injector platform that has a patient-centric structure with automated needle insertion that delivers a straightforward and uniform user experience. Moreover, in October 2021, Ypsomed launched the globe’s foremost autoinjector with integrated connectivity. It links the SmartPilot, a networked reusable extension to the YpsoMate autoinjector for including the auto-injector into a digital therapy management technique.
Additionally, the rise in infectious and chronic diseases and growing research activities are among other factors that are expected to contribute to the global market growth during the forecast period.
Stringent Regulatory Authorities
Nevertheless, rigid regulations for authorization from regulatory heads and a lack of understanding of such devices in developing and underdeveloped countries have been hindering the growth of this market.
Segment Analysis
The global self-injection device market is segmented based on product, application, distribution channel and region.
Pen Injector Product is Expected to Dominate Market
Owing to the increase in the pen injector approvals and introductions into the market the segment is estimated to dominate the global market during the forecast period. For instance, in November 2022, Tetris Pharma introduced Ogluo (glucagon prefilled autoinjector pen) for extreme hypoglycemia in children and adults with diabetes.
Also, in May 2023 Boehringer Ingelheim obtained the U.S. Food and Drug Administration (FDA) has approval for its Cyltezo Pen, a unique autoinjector choice for Cyltezo (adalimumab-adbm), an FDA-authorized Interchangeable biosimilar to Humira (adalimumab). Further, in September 2022, Terumo India, the Indian subsidiary of Terumo Corporation, a multinational leader in medical technology, launched the FineGlide, Sterile Pen Needle for individuals needing frequent insulin injections or other self-medication.
Geographical Analysis
North America is Expected to Dominate the Global Market
The North American market is expected to dominate the global autoinjectors market during the forecast period due to increasing market developments and product introductions. For example, in July 2023, Organon & Co. and Samsung Bioepis Co., Ltd. jointly introduced the HADLIMA (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab) in the United States.
The HADLIMA PushTouch Autoinjector has received the Arthritis Foundation's Ease of Use Certification, which recognizes developments that make life easier for those living with arthritis and other functional restrictions through lab and patient testing by the Intuitive Design Applied Research Institute (IDARI).
Additionally, in July 2023, Fresenius Kabi introduced its citrate-free adalimumab biosimilar IDACIO (adalimumab-aacf) for the treatment of chronic autoimmune conditions for all suitable indications of the reference product, Humira (adalimumab) in the U.S. IDACIO is available in a self-administered prefilled syringe and a self-administered pre-filled pen (autoinjector).
COVID-19 Impact Analysis
The high COVID-19 infection rate among the general population and overflow of hospitals with COVID-19 patients during peak time of COVID-19 pandemic had a negative side effect on patients with other life-threatening conditions such as anaphylaxis, as it resulted in patients hesitating to seek or delaying emergent medical care. Thus, the pandemic has led to decrease in the demand of the self-injection device, negatively impacting the global market.
Market Segmentation
By Product
• Pen Injectors
• Wearable Injectors
• Needle-Free Injectors
• Autoinjectors
By Usage
• Disposable
• Reusable
By Application
• Autoimmune Disorder
• Allergic Disorders
• Hormonal Disease
• Infectious Diseases
• Other
By Distribution Channels
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In September 2023, Ypsomed formed a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors.
• In October 2023, Enable Injections obtained FDA authorization for its enFuse injector for the delivery of Empaveli. Empaveli, commercialized by Apellis Pharmaceuticals, treats adults with paroxysmal nocturnal hemoglobinuria (PNH).
Competitive Landscape
The major global players in the market include Becton, Dickinson and Company, Ypsomed AG, Fresenius Kabi, Gerresheimer AG, Pfizer, Inc., Antares Pharma, Inc., West Pharmaceutical Services, Insulet Corporation, Owen Mumford Ltd. and SHL Group Auto.
Why Purchase the Report?
• To visualize the global self-injection device market segmentation based on product, usage, application, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of self-injection device market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global self-injection device market report would provide approximately 69 tables, 69 figures and 190 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product
3.2. Snippet by Usage
3.3. Snippet by Application
3.4. Snippet by Distribution Channels
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Product Launches
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Stringent Regulatory Authorities
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Pricing Analysis
5.3. Regulatory Analysis
5.4. Patent Analysis
5.5. Technology and Trend Analysis
5.6. Unmet Need
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
7.1.2. Market Attractiveness Index, By Product
7.2. Pen Injectors*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Wearable Injectors
7.4. Needle-Free Injectors
7.5. Autoinjectors
8. By Usage
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
8.1.2. Market Attractiveness Index, By Usage
8.2. Disposable*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Reusable
9. By Application
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Autoimmune Disorder*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Allergic Disorders
9.4. Hormonal Disease
9.5. Infectious Diseases
9.6. Other
10. By Distribution Channels
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.1.2. Market Attractiveness Index, By Distribution Channels
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Becton, Dickinson and Company, Inc.*
13.1.1. Company Overview
13.1.2. Self-injection Device Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Ypsomed AG
13.3. Fresenius Kabi, Inc.
13.4. Gerresheimer AG
13.5. Pfizer, Inc.
13.6. Antares Pharma, Inc.,
13.7. West Pharmaceutical Services
13.8. Insulet Corporation
13.9. Owen Mumford Ltd.
13.10. SHL GROUP AUTO
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us